Celldex Therapeutics to Present at Upcoming Investor Conferences
Celldex Therapeutics (NASDAQ:CLDX) has announced its upcoming participation in two major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Celldex Therapeutics (NASDAQ:CLDX) has announced its upcoming participation in two major investor conferences in March 2025. The company's management will engage in fireside chat presentations at:
- The TD Cowen 45th Annual Health Care Conference on March 4th at 1:50 p.m. ET
- The Leerink Partners Global Healthcare Conference on March 11th at 1:00 p.m. ET
Both presentations will be accessible through live webcasts on the Celldex website's 'Events & Presentations' page under the 'Investors & Media' section. Replay access will remain available for 90 days after each event.
Details
News Market Reaction – CLDX
The recorded move for CLDX in the trading session of this news was +3.36%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences:
TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET
Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 1:00 p.m. ET
Live webcasts of the presentations will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.